Actinium Pharmaceuticals, Inc. is pioneering the development of Antibody Radiation Conjugates (ARCs) through its proprietary AWE (Antibody Warhead Enabling) technology platform. This innovative approach allows for the precise targeting of cancer cells by utilizing monoclonal antibodies that bind to specific antigens on tumor surfaces. The ARCs deliver potent radioisotopes, such as Actinium-225, directly to the cancer cells, producing double-strand DNA breaks that are not repairable by the cells. This targeted radiotherapy is designed to enhance the therapeutic efficacy while minimizing damage to surrounding healthy tissues, a significant advancement over traditional external beam radiation and chemotherapy.

One of the key products in Actinium's pipeline is Iomab-B, which is currently undergoing a pivotal Phase 3 clinical trial known as SIERRA. Iomab-B is designed to facilitate access to bone marrow transplants (BMT) for patients with relapsed or refractory acute myeloid leukemia (AML) by rapidly depleting blood cancer and immune cells that express the CD45 antigen. Clinical trials have shown that Iomab-B significantly improves patient outcomes, including increased survival rates and reduced time to BMT, while also demonstrating a lower incidence of treatment-related adverse events compared to standard therapies. This positions Iomab-B as a potentially curative option for a patient population that has historically faced limited treatment options.

United States

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

Cancer

Hematologic Diseases

Actinium Pharmaceuticals, Inc.

Acute myeloid leukemia

Hematopoietic cell transplantation

Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. BC8 is linked to the radioisotope iodine-131 and once attached to its target cells emits energy that travels a relatively long distance, destroying a patient's cancer cells and ablating their bone marrow. By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid the side effects of radiation on most healthy tissues while effectively killing the patient's cancer and marrow cells.
CAR T

Iomab-B (CD45) (apamistamab-I-131)

Relapsed/refractory acute myeloid leukemia

Actimab-A + venetoclax

Actimab-A + CLAG-M

Diffuse large B cell lymphoma

Lymphoma

The Iomab-ACT program is the use of the ARC apamistamab-I-131 and is an expansion of Actinium's strategic focus on targeted conditioning that brings Actinium into the exciting field of gene therapy (GeneTx) and Adoptive Cell Therapy (ACT) including CAR-T. The Iomab-ACT program builds on Actinium's expertise in targeted conditioning gained from its development of apamistamab-I-131 for bone marrow transplant (BMT) conditioning (Iomab-B), which is being studied in an ongoing pivotal Phase 3 trial. Iomab-ACT is a natural progression of apamistamab-I-131 as conditioning is a critical step prior to bone marrow transplant, gene therapy and CAR-T. In each of these applications, the depletion of bone marrow stem cells, lymphocytes or disease or cancer cells is necessary for the new cells to engraft and the therapy to be successful. Current non-targeted chemotherapy and/or external radiation conditioning regimens are toxic, impair patients and restrict the use and efficacy of these potentially curative therapies. Actinium is committed to bringing its ARC targeted conditioning regimens to patients and advancing the fields of bone marrow transplant, GeneTx and ACT such as CAR-T.
CAR T
Gene therapy

Actinium Pharmaceuticals, Inc.

Company Details